Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Strategies for the prevention of postoperative recurrence in Crohn's disease: results of a decision analysis.

Ananthakrishnan AN, Hur C, Juillerat P, Korzenik JR.

Am J Gastroenterol. 2011 Nov;106(11):2009-17. doi: 10.1038/ajg.2011.237. Epub 2011 Jul 26.

PMID:
21788991
2.

Economic impact of combination therapy with infliximab plus azathioprine for drug-refractory Crohn's disease: a cost-effectiveness analysis.

Saito S, Shimizu U, Nan Z, Mandai N, Yokoyama J, Terajima K, Akazawa K.

J Crohns Colitis. 2013 Mar;7(2):167-74. doi: 10.1016/j.crohns.2012.04.007. Epub 2012 May 22.

PMID:
22626508
3.

Comparative cost-effectiveness of strategies to prevent postoperative clinical recurrence of Crohn's disease.

Doherty GA, Miksad RA, Cheifetz AS, Moss AC.

Inflamm Bowel Dis. 2012 Sep;18(9):1608-16. doi: 10.1002/ibd.21904. Epub 2011 Sep 8.

4.

Can mucosal healing be a cost-effective endpoint for biologic therapy in Crohn's disease? A decision analysis.

Ananthakrishnan AN, Korzenik JR, Hur C.

Inflamm Bowel Dis. 2013 Jan;19(1):37-44. doi: 10.1002/ibd.22951.

PMID:
22416019
5.

A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis.

Tsai HH, Punekar YS, Morris J, Fortun P.

Aliment Pharmacol Ther. 2008 Nov 15;28(10):1230-9. doi: 10.1111/j.1365-2036.2008.03839.x. Epub 2008 Aug 24.

6.

Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease--modelling outcomes in active luminal and fistulizing disease in adults.

Lindsay J, Punekar YS, Morris J, Chung-Faye G.

Aliment Pharmacol Ther. 2008 Jul;28(1):76-87. doi: 10.1111/j.1365-2036.2008.03709.x. Epub 2008 Apr 11.

7.

A pilot study comparing hydrocortisone premedication to concomitant azathioprine treatment in preventing loss of response to infliximab.

Mantzaris GJ, Viazis N, Petraki K, Papamichael K, Theodoropoulos I, Roussos A, Karakoidas C, Koilakou S, Raptis N, Smyrnidis A, Agalos G, Karamanolis DG.

Eur J Gastroenterol Hepatol. 2009 Sep;21(9):1042-8. doi: 10.1097/MEG.0b013e32832937e3.

PMID:
20139856
8.

Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn's disease.

Marchetti M, Liberato NL, Di Sabatino A, Corazza GR.

Eur J Health Econ. 2013 Dec;14(6):853-61. doi: 10.1007/s10198-012-0430-7. Epub 2012 Sep 14.

PMID:
22975794
9.

Management for severe Crohn's disease: a lifetime cost-utility analysis.

Jaisson-Hot I, Flourié B, Descos L, Colin C.

Int J Technol Assess Health Care. 2004 Summer;20(3):274-9.

PMID:
15446756
10.

Cost-effectiveness analysis of adjunct VSL#3 therapy versus standard medical therapy in pediatric ulcerative colitis.

Park KT, Perez F, Tsai R, Honkanen A, Bass D, Garber A.

J Pediatr Gastroenterol Nutr. 2011 Nov;53(5):489-96. doi: 10.1097/MPG.0b013e3182293a5e. Review.

PMID:
21694634
11.

Scheduled infliximab monotherapy to prevent recurrence of Crohn's disease following ileocolic or ileal resection: a 3-year prospective randomized open trial.

Yoshida K, Fukunaga K, Ikeuchi H, Kamikozuru K, Hida N, Ohda Y, Yokoyama Y, Iimuro M, Takeda N, Kato K, Kikuyama R, Nagase K, Hori K, Nakamura S, Miwa H, Matsumoto T.

Inflamm Bowel Dis. 2012 Sep;18(9):1617-23. doi: 10.1002/ibd.21928. Epub 2011 Nov 13.

PMID:
22081474
12.

Laparoscopic ileocolic resection versus infliximab treatment of distal ileitis in Crohn's disease: a randomized multicenter trial (LIR!C-trial).

Eshuis EJ, Bemelman WA, van Bodegraven AA, Sprangers MA, Bossuyt PM, van Milligen de Wit AW, Crolla RM, Cahen DL, Oostenbrug LE, Sosef MN, Voorburg AM, Davids PH, van der Woude CJ, Lange J, Mallant RC, Boom MJ, Lieverse RJ, van der Zaag ES, Houben MH, Vecht J, Pierik RE, van Ditzhuijsen TJ, Prins HA, Marsman WA, Stockmann HB, Brink MA, Consten EC, van der Werf SD, Marinelli AW, Jansen JM, Gerhards MF, Bolwerk CJ, Stassen LP, Spanier BW, Bilgen EJ, van Berkel AM, Cense HA, van Heukelem HA, van de Laar A, Slot WB, Eijsbouts QA, van Ooteghem NA, van Wagensveld B, van den Brande JM, van Geloven AA, Bruin KF, Maring JK, Oldenburg B, van Hillegersberg R, de Jong DJ, Bleichrodt R, van der Peet DL, Dekkers PE, Goei TH, Stokkers PC.

BMC Surg. 2008 Aug 22;8:15. doi: 10.1186/1471-2482-8-15.

13.

Cost-utility analysis of biologic treatments for moderate-to-severe Crohn's disease.

Tang DH, Armstrong EP, Lee JK.

Pharmacotherapy. 2012 Jun;32(6):515-26. doi: 10.1002/j.1875-9114.2011.01053.x. Epub 2012 Apr 23.

PMID:
22528603
14.

Azathioprine or ileocolic resection for steroid-dependent terminal ileal Crohn's disease? A Markov analysis.

Kennedy ED, Urbach DR, Krahn MD, Steinhart AH, Cohen Z, McLeod RS.

Dis Colon Rectum. 2004 Dec;47(12):2120-30.

PMID:
15657664
15.

[Azathioprine and mesalazine in the prevention of postsurgical recurrence of Crohn's disease: a retrospective study].

Domènech E, Scala L, Bernal I, García-Planella E, Casalots A, Piñol M, Esteve-Comas M, Cabré E, Boix J, Gassull MA.

Gastroenterol Hepatol. 2004 Dec;27(10):563-7. Spanish.

PMID:
15574279
16.

Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.

Leontiadis GI, Sreedharan A, Dorward S, Barton P, Delaney B, Howden CW, Orhewere M, Gisbert J, Sharma VK, Rostom A, Moayyedi P, Forman D.

Health Technol Assess. 2007 Dec;11(51):iii-iv, 1-164. Review.

17.

Risks and benefits of infliximab for the treatment of Crohn's disease.

Siegel CA, Hur C, Korzenik JR, Gazelle GS, Sands BE.

Clin Gastroenterol Hepatol. 2006 Aug;4(8):1017-24; quiz 976. Epub 2006 Jul 14.

PMID:
16843733
18.

Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis.

Kaplan GG, Hur C, Korzenik J, Sands BE.

Aliment Pharmacol Ther. 2007 Dec;26(11-12):1509-20. Epub 2007 Oct 11.

19.

A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine.

Dubinsky MC, Reyes E, Ofman J, Chiou CF, Wade S, Sandborn WJ.

Am J Gastroenterol. 2005 Oct;100(10):2239-47.

PMID:
16181376
20.

A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease.

Gerson LB, Robbins AS, Garber A, Hornberger J, Triadafilopoulos G.

Am J Gastroenterol. 2000 Feb;95(2):395-407.

PMID:
10685741

Supplemental Content

Support Center